{"id":"bevacizumab-as-avastin","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Hypertension"},{"rate":"20–30%","effect":"Proteinuria"},{"rate":"3–5%","effect":"Hemorrhage"},{"rate":"5–10%","effect":"Thromboembolic events"},{"rate":"0.5–2%","effect":"Gastrointestinal perforation"},{"rate":"1–3%","effect":"Wound healing complications"},{"rate":"15–25%","effect":"Fatigue"},{"rate":"10–20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and slows or halts tumor progression.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:13.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Glioblastoma"},{"name":"Metastatic renal cell carcinoma"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT02839707","phase":"PHASE2, PHASE3","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":444},{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377},{"nctId":"NCT07331883","phase":"PHASE2","title":"Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-11-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":35},{"nctId":"NCT04404881","phase":"PHASE2","title":"Bevacizumab In Hereditary Hemorrhagic Telangiectasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2020-11-23","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":33},{"nctId":"NCT04181060","phase":"PHASE3","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-28","conditions":"Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":300},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":"Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8","enrollment":24},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2431},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06703073","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-06-10","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":600},{"nctId":"NCT06701656","phase":"PHASE2","title":"JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab","status":"RECRUITING","sponsor":"PPD Development, LP","startDate":"2025-10-28","conditions":"Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)","enrollment":200},{"nctId":"NCT06252649","phase":"PHASE3","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07490262","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2026-03-31","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":680},{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT01445509","phase":"PHASE1","title":"Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-29","conditions":"Solid Tumors","enrollment":50},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT06625775","phase":"PHASE1","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","startDate":"2024-10-29","conditions":"Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":392},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT05039801","phase":"PHASE1","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-09","conditions":"Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT06133062","phase":"PHASE2","title":"Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-11-16","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":45},{"nctId":"NCT04102098","phase":"PHASE3","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-12-31","conditions":"Carcinoma, Hepatocellular","enrollment":668},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT06233942","phase":"PHASE1","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-04-12","conditions":"Advanced Solid Tumor","enrollment":308},{"nctId":"NCT07010497","phase":"PHASE2","title":"A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-03-16","conditions":"Carcinoma, Hepatocellular","enrollment":33},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT05101070","phase":"PHASE1, PHASE2","title":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Shionogi","startDate":"2022-05-30","conditions":"Solid Tumors","enrollment":282},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT07474727","phase":"PHASE2","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Multitude Therapeutics Inc.","startDate":"2026-04-01","conditions":"Colorectal Cancer","enrollment":180},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT05528952","phase":"PHASE2","title":"Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-09-27","conditions":"Hepatocellular Carcinoma","enrollment":105},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT06607458","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2025-08-05","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT06663319","phase":"PHASE1","title":"A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-15","conditions":"Colorectal Neoplasms, Gastrointestinal Neoplasms","enrollment":220},{"nctId":"NCT05862285","phase":"PHASE3","title":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-01","conditions":"Cancer","enrollment":100},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07297212","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-01-15","conditions":"Recurrent Glioblastoma","enrollment":75},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT07462143","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-04-30","conditions":"Colorectal (Colon or Rectal) Cancer","enrollment":700},{"nctId":"NCT07457775","phase":"PHASE2","title":"Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-31","conditions":"Soft Tissue Sarcoma (Excluding GIST)","enrollment":24},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT07079631","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-18","conditions":"Metastatic Colorectal Cancer","enrollment":482},{"nctId":"NCT06096779","phase":"PHASE2","title":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-07-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07333053","phase":"NA","title":"Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","status":"RECRUITING","sponsor":"Quanda Liu","startDate":"2026-03-31","conditions":"Unresectable Colorectal Cancer","enrollment":30},{"nctId":"NCT04262466","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunocore Ltd","startDate":"2020-02-25","conditions":"Select Advanced Solid Tumors","enrollment":410},{"nctId":"NCT03847428","phase":"PHASE3","title":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-29","conditions":"Hepatocellular Carcinoma","enrollment":908},{"nctId":"NCT06819007","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-19","conditions":"Ovarian Cancer","enrollment":582},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT07448922","phase":"PHASE2","title":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","startDate":"2026-03-25","conditions":"Advanced Gynecological Malignancies","enrollment":290},{"nctId":"NCT06434480","phase":"NA","title":"SBRT in HCC With Oligoprogression on First-line Immunotherapy","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-06-21","conditions":"HCC","enrollment":30},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT07225270","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy","status":"RECRUITING","sponsor":"Genmab","startDate":"2026-03-16","conditions":"Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC","enrollment":528},{"nctId":"NCT00433511","phase":"PHASE3","title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11-02","conditions":"Breast Adenocarcinoma","enrollment":4994},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07445347","phase":"","title":"Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network","status":"ENROLLING_BY_INVITATION","sponsor":"Poitiers University Hospital","startDate":"2025-10-15","conditions":"Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension, Bevacizumab","enrollment":111},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT07446387","phase":"PHASE2","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":70},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":"Colorectal Adenocarcinoma","enrollment":455},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT06303505","phase":"PHASE1, PHASE2","title":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","status":"RECRUITING","sponsor":"Tubulis GmbH","startDate":"2024-06-12","conditions":"Ovarian Cancer, Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT03115333","phase":"NA","title":"DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-07-25","conditions":"Gliosarcoma, Recurrent Glioblastoma","enrollment":146},{"nctId":"NCT05797168","phase":"PHASE1, PHASE2","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-06-05","conditions":"Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer","enrollment":506},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT05739981","phase":"PHASE1, PHASE2","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2023-02-10","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":30},{"nctId":"NCT04830709","phase":"","title":"Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-15","conditions":"Ovarian Cancer","enrollment":750},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT06888817","phase":"PHASE3","title":"Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-06-19","conditions":"Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases","enrollment":408},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT05445778","phase":"PHASE3","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-03-15","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":520},{"nctId":"NCT05488522","phase":"PHASE1","title":"SBRT With Atezo/Bev for HCC","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-09-01","conditions":"Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT05647122","phase":"PHASE1","title":"First in Human Study of AZD9592 in Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-21","conditions":"Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms","enrollment":403},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT05775159","phase":"PHASE2","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-24","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":294},{"nctId":"NCT05171660","phase":"PHASE3","title":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-02-08","conditions":"Colorectal Cancer Stage IV","enrollment":446},{"nctId":"NCT02519348","phase":"PHASE2","title":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2015-10-19","conditions":"Hepatocellular Carcinoma","enrollment":433},{"nctId":"NCT07407465","phase":"PHASE2","title":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-10-20","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT04770896","phase":"PHASE3","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-04-26","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":557},{"nctId":"NCT06750094","phase":"PHASE3","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT07263438","phase":"PHASE2","title":"Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2025-11-03","conditions":"Glioblastoma, Recurrence Tumor","enrollment":59},{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT04634578","phase":"PHASE2","title":"Bevacizumab Treatment For Type 1 ROP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2022-05-01","conditions":"Retinopathy of Prematurity","enrollment":77},{"nctId":"NCT05238922","phase":"PHASE1","title":"Study of INCB123667 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2022-07-05","conditions":"Solid Tumors","enrollment":604},{"nctId":"NCT07397819","phase":"PHASE1, PHASE2","title":"Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy","status":"RECRUITING","sponsor":"Dong sheng Zhang","startDate":"2025-11-28","conditions":"Malignant Ascites","enrollment":48},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT07323576","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-02-01","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03896074","phase":"PHASE2","title":"Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2020-03-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1587,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bevacizumab as Avastin","genericName":"Bevacizumab as Avastin","companyName":"Mylan Pharmaceuticals Inc","companyId":"mylan-pharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}